1. Home
  2. PFAI vs CUE Comparison

PFAI vs CUE Comparison

Compare PFAI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFAI

Pinnacle Food Group Limited

N/A

Current Price

$2.26

Market Cap

27.1M

ML Signal

N/A

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$0.31

Market Cap

27.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PFAI
CUE
Founded
2015
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
27.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PFAI
CUE
Price
$2.26
$0.31
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.00
AVG Volume (30 Days)
3.5K
316.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
35.14
EPS
N/A
N/A
Revenue
N/A
$9,287,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
69.16
52 Week Low
$1.30
$0.23
52 Week High
$4.93
$1.12

Technical Indicators

Market Signals
Indicator
PFAI
CUE
Relative Strength Index (RSI) 51.51 47.64
Support Level $2.22 $0.29
Resistance Level $2.35 $0.36
Average True Range (ATR) 0.11 0.02
MACD -0.00 0.00
Stochastic Oscillator 68.57 73.35

Price Performance

Historical Comparison
PFAI
CUE

About PFAI Pinnacle Food Group Limited

Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: